Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...